Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules.

BACKGROUND The association between autoimmune thyroiditis (AIT) and thyroid cancer is still not clear despite many previous reports. This study investigated whether serologic thyroid antibodies are predictive of thyroid cancer in patients with thyroid nodules. METHOD We retrospectively reviewed records of patients with thyroid nodules evaluated by ultrasonography-guided fine-needle aspiration cytology at our institution between January 2006 and December 2008. Thyroid autoimmunity was assessed by measuring thyroglobulin antibody (TgAb) and thyroid peroxidase antibody (TPOAb). The final outcome deciding a benign or malignant status involved a combination of cytology and histology. RESULTS Of the 1638 patients, malignant nodules had a higher rate of positive TgAb (30.8% vs. 19.6%; p < 0.001) and elevated thyrotropin (TSH) levels (2.5 +/- 2.8 mIU/L vs. 2.1 +/- 2.0 mIU/L; p = 0.021) than benign nodules. The rate of positive TPOAb was not higher in malignant nodules, although both TPOAb and TgAb were well correlated with TSH levels and histological AIT. In the multivariate analysis, a positive TgAb was significantly associated with thyroid cancer (odds ratio [OR] = 1.61, 95% confidence interval [CI] 1.12-2.33) with upper tertile of normal range of TSH levels (OR = 1.72, 95% CI 1.12-2.63) and above normal range of TSH levels (OR = 1.98, 95% CI 1.06-3.70). CONCLUSION We report for the first time that a positive serum TgAb test was an independent predictor for thyroid malignancy in thyroid nodules along with serum TSH levels regardless of the presence of AIT. Our results suggest that TgAb measurement could give additional information for predicting malignancy in cytologically indeterminate thyroid nodules in conjunction with clinical risk factors and TSH levels.

[1]  D. Lee,et al.  Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation , 2002, Clinical endocrinology.

[2]  L. Woolner,et al.  Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. , 1986, Mayo Clinic proceedings.

[3]  O. Sheils.  Molecular classification and biomarker discovery in papillary thyroid carcinoma , 2005, Expert review of molecular diagnostics.

[4]  C. McHenry,et al.  The incidence of thyroid carcinoma in Hashimoto's thyroiditis. , 1987, The American surgeon.

[5]  O. Sheils,et al.  Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[6]  J. Jonklaas,et al.  Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[7]  J. Shah,et al.  Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. , 1999, Surgery.

[8]  L. Hegedüs,et al.  Thyroid Ultrasound , 2019, Springer International Publishing.

[9]  J. Baker.  The immune response to papillary thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[10]  E. Alexander,et al.  Approach to the patient with a cytologically indeterminate thyroid nodule. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  P. Walfish,et al.  Non-diagnostic fine needle aspiration biopsy: a dilemma in management of nodular thyroid disease. , 1993, The American surgeon.

[12]  B. Cha,et al.  Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. , 2007, Thyroid : official journal of the American Thyroid Association.

[13]  A. Belfiore,et al.  Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. , 1992, The American journal of medicine.

[14]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[15]  C. Spencer.  Laboratory support for the diagnosis and monitoring of thyroid disease , 2009 .

[16]  E. Castanas,et al.  Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. , 1980, The Journal of clinical endocrinology and metabolism.

[17]  A. Pinchera,et al.  Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. , 2009, Endocrine-related cancer.

[18]  W. Wiersinga,et al.  Risk factors for and prevalence of thyroid disorders in a cross‐sectional study among healthy female relatives of patients with autoimmune thyroid disease , 2003, Clinical endocrinology.

[19]  E. Vignali,et al.  Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens , 2003, Annals of Internal Medicine.

[20]  Tae Yong Kim,et al.  Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[21]  S. Filetti,et al.  High frequency of cancer in cold thyroid nodules occurring at young age. , 1989, Acta endocrinologica.

[22]  Herb Chen,et al.  Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension , 2009, Clinical endocrinology.

[23]  A. Pinchera,et al.  Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. , 2008, The Journal of clinical endocrinology and metabolism.

[24]  M. Fujiwara,et al.  Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans , 1995, Cancer.

[25]  H. Blomgren,et al.  Cancer risks in patients with chronic lymphocytic thyroiditis. , 1985, The New England journal of medicine.

[26]  A. Gawande,et al.  Long‐term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation , 2007, Cancer.

[27]  D. Sinclair.  Clinical and laboratory aspects of thyroid autoantibodies , 2006, Annals of clinical biochemistry.

[28]  G. Crile.  Struma lymphomatosa and carcinoma of the thyroid. , 1978, Surgery, gynecology & obstetrics.

[29]  P. Unger,et al.  Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? , 2003, Human pathology.

[30]  M. Santoro,et al.  Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis , 1997, The Laryngoscope.

[31]  H. Vierhapper,et al.  Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. , 2000, Thyroid : official journal of the American Thyroid Association.

[32]  M. Nikiforova,et al.  Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas , 2002, International journal of surgical pathology.

[33]  E. A. Gaston,et al.  The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. , 1968, Annals of internal medicine.

[34]  P. Larsen,et al.  Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. , 2006, The Journal of clinical endocrinology and metabolism.

[35]  P. Larsen,et al.  Natural History of Benign Solid and Cystic Thyroid Nodules , 2003, Annals of Internal Medicine.

[36]  S. Diaz-Cano,et al.  Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. , 2002, Histopathology.

[37]  J. Hazard,et al.  Incidence of cancer in struma lymphomatosa. , 1962, Surgery, gynecology & obstetrics.

[38]  Herb Chen,et al.  Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. , 2008, The Journal of clinical endocrinology and metabolism.

[39]  P. Ungaro,et al.  Cancer in thyroid nodules. A community hospital survey. , 1984, Archives of internal medicine.

[40]  D. Appleton,et al.  THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY , 1977, Clinical endocrinology.

[41]  P Berti,et al.  Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy , 2007, Clinical endocrinology.

[42]  P. Singer,et al.  Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[43]  M. Homma,et al.  Presence of TSH receptor in thyroid neoplasms. , 1976, The Journal of clinical endocrinology and metabolism.

[44]  T. Jørgensen,et al.  Risk factors for goiter and thyroid nodules. , 2002, Thyroid : official journal of the American Thyroid Association.

[45]  F I Gilbert,et al.  The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto's thyroiditis. , 1993, Archives of internal medicine.

[46]  C. Harmer,et al.  Thyroglobulin antibodies in differentiated thyroid cancer. , 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

[47]  J. Franklyn,et al.  Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. , 2006, The Journal of clinical endocrinology and metabolism.

[48]  S. Lindsay,et al.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. , 1955, A.M.A. archives of surgery.

[49]  A. Lawrence,et al.  The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. , 1985, Surgery.

[50]  L. Crapo,et al.  The epidemiology of thyroid disease and implications for screening. , 1997, Endocrinology and metabolism clinics of North America.